Stockscreener 앱 받기
40.84
0.01%
-0.005
시간 외 거래:
40.83
-0.015
-0.04%
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Mizuho reiterates Apellis stock rating citing M&A process details - Investing.com
Mizuho reiterates Apellis stock rating citing M&A process details By Investing.com - Investing.com Canada
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD - Investing.com
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD By Investing.com - Investing.com UK
M&A Class Action Firm Investigating Multiple Mergers - National Today
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Apellis (APLS) board recommends $41 cash takeover by Biogen with up to $4 CVR - Stock Titan
Biogen (NASDAQ: APLS) bids $41 per share plus up to $4 CVR for Apellis - Stock Titan
Wellington Management Group LLP Significantly Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus
Support Test: Can Apellis Pharmaceuticals Inc stock outperform in a bear marketMarket Weekly Review & Precise Buy Zone Tips - baoquankhu1.vn
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Valuation Update: Does Apellis Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Sahm
US Market Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsQuarterly Portfolio Report & High Return Trade Guides - baoquankhu1.vn
Apellis (APLS) director shifts 5,750 trust shares to spouse account - Stock Titan
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Trading the Move, Not the Narrative: (APLS) Edition - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - Sahm
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Apellis Pharmaceuticals Stock Rockets 140% With 6-Day Winning Streak - Trefis
6-Day Rally Sends Apellis Pharmaceuticals Stock Up 140% - Trefis
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 By Investing.com - Investing.com Australia
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 - Investing.com
Retail Surge: Can Apellis Pharmaceuticals Inc grow without dilution2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
RBC Adjusts Price Target on Apellis Pharmaceuticals to $41 From $21, Maintains Sector Perform Rating - marketscreener.com
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
Apellis Pharmaceuticals Acquisition Under Investigation - National Today
Wellington files 13G/A owning 249,635 shares of Apellis (APLS) - Stock Titan
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a ... - Bluefield Daily Telegraph
Shareholder Alert: Ademi LLP investigates whether Apellis - GlobeNewswire
5-Day Rally Sends Apellis Pharmaceuticals Stock Up 139% - Trefis
Apellis Pharmaceuticals Stock Surges 139%, With A 5-Day Winning Spree - Trefis
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView — Track All Markets
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Apellis surges on $5.6B buyout deal with Biogen - MSN
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
TD Cowen Maintains Apellis Pharmaceuticals (APLS) Buy Recommendation - MSN
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
2.69%
0.25%
자본화:
|
볼륨(24시간):